Skip to content

Evaluating the Effects of Melatonin Supplementation on Anxiety and Depression in Patients with Breast Cancer

Evaluating the Effects of Melatonin Supplementation on Anxiety and Depression in Patients with Breast Cancer, a Randomized Clinical Trial Study

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20240304061165N1
Enrollment
76
Registered
2024-07-13
Start date
2024-07-20
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Anxiety. Condition 2: Depression. Condition 3: Breast Cancer. Condition 4: Mixed Anxiety and Depression. Adjustment disorder with anxiety Adjustment disorder with depressed mood Malignant neoplasm of breast Adjustment disorder with mixed anxiety and depressed mood

Interventions

Sponsors

Sabzevar University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Informed consent to participate in the study. Patients with breast cancer under follow-up who have been treated for three months based on pathology results and were disease-free at the time of examination. People without diabetes, high blood pressure, cardiovascular diseases, kidney disease, liver disease, acute diseases, autoimmune disease, thyroid disorder, mental disorders

Exclusion criteria

Exclusion criteria: Patients with known underlying diseases including uncontrolled diabetes, uncontrolled high blood pressure, cardiovascular diseases, chronic kidney disease, chronic liver disease, autoimmune disease, thyroid disorder, and the use of uncontrolled psychiatric drugs. Unwillingness to continue cooperation in the project Diagnosis of metastasis Causing severe toxicities that could not be controlled with usual doses, such as nausea

Design outcomes

Primary

MeasureTime frame
Depression. Timepoint: Day 0 and 30 of intervention. Method of measurement: Beck's Depression Inventory (BDI).;Anxiety. Timepoint: Day 0 and 30 of intervention. Method of measurement: Beck's Anxiety Inventory (BAI).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactVida Fazliani Moghaddam

Sabzevar University of Medical Sciences

VidaFazliani@gmail.com+98 51 4261 0965

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026